Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous total tumor RNA-loaded monocyte-derived mature dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Vrije University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The **autologous total tumor RNA-loaded monocyte-derived mature dendritic cell vaccine** is an investigational, patient-specific cellular immunotherapy developed by the Academisch Medisch Centrum (AMC, Amsterdam UMC). Classified as an Advanced Therapy Medicinal Product (ATMP), this personalized vaccine is manufactured by extracting peripheral blood monocytes from a patient via leukapheresis, differentiating them ex vivo into mature dendritic cells, and loading them with the full repertoire of tumor-associated antigens via electroporation or pulsing with total tumor RNA extracted from the patient's own tumor tissue. The vaccine is designed to activate tumor-antigen-specific cytotoxic T lymphocytes (CTLs), thereby inducing a robust anti-tumor immune response tailored to the patient's unique tumor profile. It has been primarily studied in manufacturing-validation clinical trials for the treatment of esophageal adenocarcinoma and pancreatic cancer.
- Other names
- autologous tumor RNA-loaded dendritic cell vaccinetotal tumor RNA-loaded DC vaccine
02
Targets
Tumor cells expressing the corresponding autologous tumor antigensPatient-specific tumor-derived peptide-MHC complexes recognized by T-cell receptors
Beyond the preview
Go deeper on autologous total tumor RNA-loaded monocyte-derived mature dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous total tumor RNA-loaded monocyte-derived mature dendritic cell vaccine.